Daewoong Pharmaceutical Co., Ltd. Announces Continuation of Global Phase 2 Clinical Trial for Bersiporocin
Daewoong Pharmaceutical announced that its idiopathic pulmonary fibrosis (IPF) drug candidate Bersiporocin received a recommendation to continue its global Phase 2 clinical trial following a positive safety review by the third Independent Data Monitoring Committee (IDMC).
The IDMC conducted an in-depth evaluation of interim safety data from 89 enrolled patients and found no significant safety concerns. To date, Daewoong has enrolled 94 participants, representing approximately 92% of the target population (102 patients).
The study is progressing as planned.
- 94 patients enrolled out of 102 planned across Korea and the U.S.
- Third IDMC review confirms safety and continuation of the study
Author's summary: Daewoong Pharmaceutical continues global Phase 2 trial for Bersiporocin.
More News
- CSL Earnings Slashed Amidst Vaccination Decline - Sharecafe
- Venture Capital, Moonshots, and AI: The 2025 Tech Soap Opera
- The AI Gender Gap Paradox (SSIR)
- Massive shake-up for Whangarei finale
- In Anish Kapoor’s Hands, an Offshore Gas Rig Became a Call for Climate Accountability
- Giving States Waivers From Accountability Is a Dangerous Step Backward for Kids
- Richard White targeted as federal police raid WiseTech
- From decline to renewal: Why leadership still matters
- Ranji Trophy 2025/26The Shillong Times
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups